
The American Cancer Society (ACS) has significantly updated its guidelines for prostate cancer screening, explicitly recommending regular prostate-specific antigen (PSA) blood tests for both average-risk and high-risk men. The new guidance, published this week in CA: A Cancer Journal for Clinicians, marks a major shift from previous protocols that relied heavily on shared decision-making without providing specific routine testing intervals.
Under the updated 2026 guidelines, average-risk men between the ages of 50 and 69 should undergo PSA-based screening every two years. For men at a higher risk of developing the disease—including Black men and those with a strong family history of prostate cancer—the ACS now recommends annual screening beginning at age 45 and continuing through age 69.
The shift comes amid clinical advancements in understanding how to leverage the PSA test effectively while minimizing the potential harms of overdiagnosis and overtreatment. “Think of prostate cancer screening as an early warning system for your health,” Dr. Shanthi Sivendran, interim chief patient officer for the ACS, said in a statement. “By catching aggressive cancers with a simple PSA blood test, you open the door to highly effective treatments that protect your future. Meanwhile, lower-risk findings can be safely managed through careful, active surveillance.”
The guidelines also specifically address older demographics. For men aged 70 to 74, the ACS recommends individualized decision-making with a doctor to weigh the continuing benefits against the risks of screening. However, the organization explicitly discourages routine screening for men aged 75 and older, as well as for any man who is not expected to live another ten years due to other underlying health issues.
To mitigate the risk of unnecessary and invasive biopsies, the updated protocol includes new diagnostic steps for those with elevated results. Men who return a high PSA level are now advised to undergo a repeat test within two weeks to three months to confirm the result. If the levels remain elevated, doctors should offer an MRI scan or a validated biomarker test to guide the decision on whether a physical biopsy is actually required.
Prostate cancer remains one of the most common cancers among men. The ACS estimates that more than 333,000 men in the United States will be diagnosed with prostate cancer in 2026, and approximately 36,000 will die from the disease.

